Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
BeOne Medicines
Eli Lilly and Company
Pheast Therapeutics
ALX Oncology Inc.
R-Pharm
Dispatch Biotherapeutics
Context Therapeutics Inc.
Kivu Bioscience Inc.
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
NiKang Therapeutics, Inc.
Novartis
EMD Serono
Bayer
Kumquat Biosciences Inc.
City of Hope Medical Center
National Institutes of Health Clinical Center (CC)
Seagen Inc.
City of Hope Medical Center
Seagen Inc.
Seagen Inc.
National Institutes of Health Clinical Center (CC)
Seagen Inc.
Pliant Therapeutics, Inc.
Pfizer
Eli Lilly and Company
Eli Lilly and Company
Pfizer
Qilu Hospital of Shandong University
City of Hope Medical Center
BioNTech SE
Aurigene Discovery Technologies Limited
Aurigene Discovery Technologies Limited
BeOne Medicines
Bristol-Myers Squibb
MOMA Therapeutics
The Methodist Hospital Research Institute
Eli Lilly and Company
Pheon Therapeutics
Eli Lilly and Company
AstraZeneca
M.D. Anderson Cancer Center
Novartis
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Zhejiang Provincial People's Hospital
Kivu Bioscience Inc.
M.D. Anderson Cancer Center